How the EU's Health Technology Assessment Regulation Is Creating New Regulatory Affairs Work

Introduction

For most of the European Union's history, a new medicine's path to patients ran through two largely separate systems. The European Medicines Agency decided whether a product was safe and effective enough to be authorized. Then, country by country, national health technology assessment (HTA) bodies decided whether it was worth paying for, each running its own clinical evaluation, often asking for different comparators, different endpoints, and different formats. A sponsor filing in twenty member states could end up assembling something close to twenty different clinical dossiers for the same product.

The EU's Health Technology Assessment Regulation, Regulation (EU) 2021/2282, is the first serious attempt to collapse that duplication. It entered into application in January 2025 for oncology medicines and advanced therapy medicinal products going through the EMA's centralized authorization procedure, with other product categories joining in phases over the rest of the decade. For regulatory affairs professionals, it is not just a market access curiosity. It changes what gets submitted, when, and by whom, and it is opening up a genuinely new lane of work that sits right at the boundary between regulatory and market access.

What the Regulation Actually Does

At the center of the new system is the Joint Clinical Assessment, or JCA. Instead of each member state's HTA body independently assessing a product's relative clinical effectiveness, a coordination group made up of representatives from national HTA bodies now produces a single joint clinical assessment report. That report covers the clinical evidence question, how does this product perform against the clinical alternatives, and it is meant to be used, not re-litigated, by every member state's own HTA process afterward.

Member states keep full control over the parts of HTA that were always the more politically sensitive ones anyway: cost-effectiveness analysis, budget impact, and the ultimate pricing and reimbursement decision. The joint part of the system is strictly the clinical evidence assessment. That division matters for how companies staff and plan around it. The JCA is a scientific and procedural exercise that runs on a timeline closely tied to the EMA's centralized marketing authorization process; the downstream pricing and reimbursement negotiations remain a national affair with national timelines and national stakeholders.

The regulation also establishes Joint Scientific Consultations, a mechanism that lets a sponsor get early, non-binding advice from the HTA coordination group, run in parallel with EMA scientific advice, well before a marketing authorization application is filed. The intent is to reduce the odds of running a clinical development program that satisfies the regulator but leaves HTA bodies unconvinced on the comparator or endpoint choice, a mismatch that has quietly derailed market access for more than one well-approved product.

The Phased Rollout, and Why the Sequencing Matters

The regulation did not switch on for every product at once, and the sequencing tells you where hiring pressure shows up first. Oncology medicines and advanced therapy medicinal products, cell and gene therapies in particular, were first in line starting in January 2025. Orphan medicinal products are scheduled to join in 2028, and the system is set to extend to all centrally authorized medicinal products by 2030.

That phasing means the earliest wave of JCA experience is concentrating in oncology and ATMP-focused regulatory and market access teams, often inside companies that are already managing some of the most procedurally complex submissions in the industry. Those teams are the ones building the internal playbooks now: how to scope a PICO (population, intervention, comparator, outcome) framework that will satisfy more than two dozen national perspectives on what the relevant comparator even is, how to time JCA-related evidence generation against the pivotal trial design, and how to keep the clinical dossier consistent across the EMA submission and the joint assessment file without duplicating effort twice.

What This Means for Regulatory Affairs Roles

The most immediate effect is a new category of cross-functional work that did not cleanly exist before. Classic regulatory affairs expertise, built around EMA procedures, dossier structure, and interactions with assessors, is necessary but not sufficient for JCA submissions. The PICO scoping exercise in particular draws on skills that used to live almost entirely in health economics and outcomes research or market access functions: understanding comparative effectiveness literature, anticipating where national HTA bodies are likely to diverge on an acceptable comparator, and building evidence packages that can withstand scrutiny from reviewers who are not evaluating safety and efficacy in the regulatory sense at all, but relative clinical benefit.

Companies are responding in a few different ways, and none of them has fully standardized yet. Some are building dedicated JCA or EU HTA submission teams that sit organizationally close to regulatory affairs but report through market access. Others are cross-training senior regulatory affairs professionals who already run centralized procedure submissions, on the theory that the procedural literacy, document management discipline, and EMA interaction experience transfer directly, and the health economics pieces can be filled in with specialist support. Consultancies and CROs that previously offered HTA services as an adjunct to pricing and reimbursement work are expanding into JCA-specific advisory practices, which has created an active market for contract and consulting talent with early JCA exposure.

What is consistent across all of these approaches is demand for people who are genuinely bilingual between regulatory and market access vocabularies. A regulatory professional who understands why a particular comparator choice in a clinical trial protocol will matter to a joint assessment report two years later, long before the marketing authorization application is even filed, is unusually valuable right now, precisely because that kind of foresight used to live in a different department and arrive too late to change the trial design.

Practical Implications for Job Seekers

If you already work in EU regulatory affairs, the most direct way to build relevant experience is to get close to any oncology or ATMP program at your company and ask to be looped into JCA planning discussions, even if the formal submission work isn't owned by your team yet. Understanding how PICO scoping decisions get made, and who in the organization makes them, is more valuable right now than any credential, because the processes are still being worked out company by company.

If you are earlier in your career or coming from a market access or health economics background and want to move toward regulatory affairs, the EU HTA Regulation is one of the more natural bridges available. The joint clinical assessment process genuinely needs people who can read a clinical trial protocol with a regulator's eye and a payer's skepticism at the same time, and there is not yet a deep bench of people who have done that specific job for more than a couple of submission cycles.

It's also worth watching how the 2028 and 2030 expansion dates affect hiring. Orphan medicinal products joining the JCA system in 2028 will pull rare disease-focused regulatory and market access teams into this work on a similar timeline to what oncology and ATMP teams are navigating now, and the 2030 expansion to all centrally authorized products means that, eventually, JCA literacy stops being a specialist niche and becomes baseline EU regulatory affairs competency. Positioning yourself as someone with early, direct JCA experience now is a reasonable bet on where the skill requirement is heading for the whole field, not just one therapeutic area.

How JCA Timing Interacts With the EMA Procedure

One detail that trips up teams encountering this for the first time is just how tightly the JCA calendar is bound to the centralized authorization procedure. The coordination group's assessment work is designed to run in parallel with the EMA's scientific review rather than as a sequential step afterward, which means the clinical dossier submitted for the joint assessment has to be prepared on essentially the same timeline as the marketing authorization application itself, not revisited once a CHMP opinion is already in hand. That has real organizational consequences: a regulatory affairs team used to treating HTA engagement as something that starts in earnest only after approval now has to plan JCA-relevant evidence packaging alongside the MAA submission, with document finalization deadlines that leave very little room for late changes to comparator selection or outcome reporting.

This is also where a lot of the new hiring need actually shows up. It is less about finding people to handle a brand-new standalone workstream after launch, and more about finding people who can sit inside the existing EU submission planning process and make sure the JCA-relevant evidence questions get asked at the protocol design stage, not discovered as a gap once the clinical study report is already finalized. Companies that treat the JCA as a bolt-on exercise handled entirely by a separate team after the fact tend to run into exactly the kind of late-stage scrambling the regulation was partly designed to prevent.

Conclusion

The EU's Health Technology Assessment Regulation is easy to underestimate from a pure regulatory affairs vantage point, because its headline purpose, reducing duplicated HTA work across member states, sounds like a market access story rather than a submissions one. But the joint clinical assessment runs on a timeline tied to the centralized marketing authorization procedure, draws on evidence generated during the same clinical development program regulatory affairs teams are already managing, and requires the kind of early, cross-functional planning that regulatory professionals are well positioned to lead if they move early. For anyone building a career around EU submissions work, understanding the JCA process now, while the playbooks are still being written, is a genuine opportunity rather than just another compliance obligation to absorb.